Anika's Cingal misses in Phase III for osteoarthritis knee pain

Anika Therapeutics Inc. (NASDAQ:ANIK) was off $9.62 (21%) to $36.50 in after-hours trading Tuesday after reporting that Cingal missed the primary

Read the full 219 word article

User Sign In